

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Biocompatibles Inc. dba Advanced Care Medical/BrachySciences</p> <p>2. 115 Hurley Road, Building 3A Oxford, Connecticut 06478</p>	<p>In accordance with the letter dated August 3, 2009,</p> <p>3. License number 06-30764-02MD is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date December 31, 2012</p> <hr/> <p>5. Docket No. 030-36179 Reference No.</p>
---	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Palladium 103</p> <p>B. Iodine 125</p> <p>C. Cesium 131</p>	<p>7. Chemical and/or physical form</p> <p>A. Sealed Source</p> <p>B. Sealed Source</p> <p>C. Sealed Source</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. See Condition 10</p> <p>B. See Condition 10</p> <p>C. See Condition 10</p>
--	---	--

9. Authorized use:

A. and B. Pursuant to 10 CFR 32.74, the licensee is authorized to distribute the licensed material described in Items 6 and 7 of this license to persons licensed pursuant to 10 CFR 35.400, or under equivalent licenses of any Agreement State.

CONDITIONS

10. Each sealed source distributed pursuant to the conditions of this license shall be in accordance with the following table:

<u>Isotope</u>	<u>Source Model Number</u>	<u>Maximum Activity Per Source</u>
Pd-103	IsoAid IAPd-103A	15 millicuries
Pd-103	(NASI) MED3633	25 millicuries
Pd-103	Theragenics Model 200	10 millicuries
I-125	Medi-Physics Inc. 6702	195 millicuries
I-125	Medi-Physics Inc. 6711	270 millicuries

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
06-30764-02MD

Docket or Reference Number
030-36179

Amendment No. 9

<u>Isotope</u>	<u>Source Model Number</u>	<u>Maximum Activity Per Source</u>
I-125	Medi-Physics Inc. 6733 (EchoSeed)	71.2 millicuries
I-125	North American Scientific Inc. MED3631	25 millicuries
I-125	Best Medical International 2300 Series	110 millicuries
I-125	Bebig 125-S06	40 millicuries
I-125	Mills Biopharmaceuticals Inc. 125SL	1 millicurie
I-125	Mills Biopharmaceuticals Inc. 125SH	150 millicuries
I-125	IsoAid Inc. 1A1-125A	10 millicuries
I-125	Implant Sciences Corp. Model 3000	5 millicuries
I-125	Implant Sciences Corp. Model 3500	7.5 millicuries
I-125	International Brachytherapy, SA 1251L	5.5 millicuries
I-125	Source Tech Medical, LLC STM125	15 millicuries
I-125	Draximage Inc. LS-1	75 millicuries
Cs-131	IsoRay Model Cs-1	65 millicuries

11. The licensee may distribute only from its facilities located at 115 Hurley Road, Building 3A, Oxford, Connecticut.
12. This license does not authorize possession or use of licensed material.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
06-30764-02MDDocket or Reference Number
030-36179

Amendment No. 9

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated August 9, 2002 [ML022340699]
 - B. Facsimile received September 5, 2002, except attachments [ML023580358]
 - C. Letter dated December 7, 2002 [ML023430482]
 - D. Letter dated July 28, 2003 [ML032100538]
 - E. Letter dated September 19, 2003 [ML032680907]



For the U.S. Nuclear Regulatory Commission

Date September 22, 2009

By

Original signed by Elizabeth Ullrich

Elizabeth Ullrich
Commercial and R&D Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406